A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

M. B. Bornstein, A. Miller, S. Slagle, M. Weitzman, E. Drexler, M. Keilson, V. Spada, W. Weiss, Stanley H. Appel, L. Rolak, Y. Harati, S. Brown, R. Arnon, I. Jacobsohn, D. Teitelbaum, M. Sela

Research output: Contribution to journalArticle

159 Scopus citations

Abstract

We found Cop 1 to be effective and relatively safe in a previous (exacerbating-remitting) clinical trial. This current trial involves 106 chronic-progressive patients. The major end point, confirmed progression of 1.0 or 1.5 units (depending on baseline disability) on the Kurtzke Expanded Disability Status Scale, was observed in nine (17.6%) treated and 14 (25.5%) control patients. The differences between the overall survival curves were not significant. Progression rates at 12 and 24 months were higher for the placebo group (p = 0.088) with 2-year probabilities of progressing of 20.4% for Cop 1 and 29.5% for placebo. We found a significant difference at 24 months between placebo and Cop 1 at one but not the other center. Two-year progression rates for two secondary end points, unconfirmed progression, and progression of 0.5 EDSS units, (p = 0.03) are significant.

Original languageEnglish (US)
Pages (from-to)533-539
Number of pages7
JournalNeurology
Volume41
Issue number4
DOIs
StatePublished - Apr 1991

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis'. Together they form a unique fingerprint.

Cite this